Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 33, 2019 - Issue 13
166
Views
7
CrossRef citations to date
0
Altmetric
Research Articles

A new alkylbenzoquinone from Embelia rowlandii Gilg. (Myrsinaceae)

, , , , , , , & show all
Pages 1909-1915 | Received 03 Apr 2018, Accepted 18 May 2018, Published online: 25 May 2018
 

Abstract

A new alkylbenzoquinone named embeliquinone (1) together with five known compounds, lupeol (2), 3-O-[6′-O-palmitoyl-β-d-glucosyl]-spinasta-7,22(23)-diene (3), quercetin (4), (2S,3S,4R,8E)-2-[(2′R)-2′-hydroxy-heneicosanoylamino]-heneicosane-1,3,4-triol-8-ene (5), and β-sitosterol-3-O-β-d-glucopyranoside (6) were isolated from the MeOH leaf extract of Embelia rowlandii by using repeated open column chromatography techniques. The structure of the new compound was characterized by analyses of 1D- and 2D-NMR, and MS data. Embeliquinone (1) had moderate anti-cell proliferation activity against A549 cell line with the IC50 value of 21.8 μM. In addition, 1 exhibited weak antibacterial activities against Klebsiella pneumoniae and Staphylococcus aureus with an MIC value of 206.0 μM in both cases.

Acknowledgements

The International Foundation for Sciences (IFS) and the Organization for the Prohibition of Chemical Weapons (OPCW) are acknowledged by Dr. Blanche L. Ndontsa for financial support. Dr. Maurice D. Awouafack is grateful to the Japan Society for the Promotion of Science for Postdoctoral Fellowship awarded as Overseas Researcher (P16411) to work at the Institute of Natural Medicine, University of Toyama.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.